WO 2018/037310 Al 01 March 2018 (01.03.2018) W !P O PCT
Total Page：16
File Type：pdf, Size：1020Kb
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/037310 Al 01 March 2018 (01.03.2018) W !P O PCT (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, A61K 47/14 (2017.01) A61K 31/4166 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, A61K 9/08 (2006.01) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/IB20 17/054945 Published: (22) International Filing Date: — with international search report (Art. 21(3)) 14 August 2017 (14.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201621028407 20 August 2016 (20.08.2016) IN (71) Applicant: FTF PHARMA PRIVATE LIMITED [IN/IN]; Sarkhej-Rajkot highway, at village: Navapura, taluka: Sanand, dist: Ahmedabad, Gujarat, Ahmedabad 382210 (IN). (72) Inventors: PATEL, Nileshkumar Bhikhabhai; C-401, SHLOK RESIDENCY, NEAR AYODHYANAGARI SOCIETY, NEW RANIP, AHMEDABAD, GUJARAT, INDIA, AHMEDABAD 382470 (IN). GURJAR, Lalc- hand Dataram; Near to Hans Satsang Bhawan, Village - Putli, Tehsil- Kotputli, District- Jaipur, Rajasthan, Putli 303 108 (IN). MANDAL, Jayanta Kumar; A - 44, Orchid Park, Nr Anjani Tower, Ramdev Nagar, Satelite, Ahmed abad, Ahmedabad 380015 (IN). (74) Agent: BABARIA, Ketana; Ketana Laljibhai Babaria, B - 137, Harisiddha Park, Nr. Nav Sarjan School, Ranip, Ahmedabad Gujarat, India, Ahmedabad 382480 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, < TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, © (54) Title: PHARMACEUTICAL COMPOSITION COMPRISING AN ANDROGEN RECEPTOR INHIBITOR (57) Abstract: The present invention relates to the oral pharmaceutical composition comprising an androgen receptor inhibitor and one © or more pharmaceutically acceptable excipients selected from the group comprising of fillers/vehicles, solvents/co-solvents, preserva- 00 tives/antioxidants, surfactants, buffering agents, chelating agents, sweetening agents, flavouring agents, sweetness/flavour enhancing o agents, or combinations thereof. The present invention also relates to the processes for the preparation of the oral pharmaceutical com position comprising androgen receptor inhibitor and one or more pharmaceutically acceptable excipients. o PHARMACEUTICAL COMPOSITION COMPRISING AN ANDROGEN RECEPTOR INHIBITOR FIELD OF THE INVENTION The present invention relates, in general, to the pharmaceutical field, and more precisely it relates to a pharmaceutical composition for the oral administration of Androgen Receptor Antagonists and to the process for the preparation thereof. In particular, the present invention relates to the oral liquid composition comprising Enzalutamide. BACKGROUND OF THE INVENTION The Androgen Receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a type of nuclear receptor that is activated by binding either of the androgenic hormones, testosterone, or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. The androgen receptor is most closely related to the progesterone receptor, and progestins in higher dosages can block the androgen receptor. The main function of the androgen receptor is as a DNA-binding transcription factor that regulates gene expression; however, the androgen receptor has other functions as well. Androgen regulated genes are critical for the development and maintenance of the male sexual phenotype. The Androgen Receptor is important for therapeutic target in prostate cancer, thus many different inhibitors have been developed, primarily targeting the ligand binding domain of the protein, while inhibitors that target the N-terminal domain of the protein are still under development. AR ligands can either be classified based on their structure (steroidal or non-steroidal) or based on their ability to activate or inhibi transcription (agonists or antagonists). Prostate cancer is the most common incidence of cancer and the second leading cause of cancer death in Western men. When the cancer is confined locally the disease can be cured by surgery or radiation. However, 30% of such cancer relapses with distant metastatic disease and others have advanced disease at diagnoses. Advanced disease is treated by castration and/or administration of antiandrogens, the so-called androgen deprivation therapy. Castration lowers the circulating levels of androgens and reduces the activity of androgen receptor (AR). Administration of antiandrogens blocks AR function by competing away androgen binding, therefore, reducing the AR activity. Although initially effective, these treatments quickly fail and the cancer becomes hormone refractory. Overexpression of AR has been identified and validated as a cause of hormone refractory prostate cancer. See Chen, C. D., Welshie, D. S., Tran, C , Baek, S. H., Chen R. Vessella, R., Rosenfeld, M. G., and Sawyers, C. L., Molecular determinants of resistance to an antiandrogen therapy, Nat. Med., 10: 33-39, 2004, which is hereby incorporated by reference. Overexpression of AR is sufficient to cause progression from hormone sensitive to hormone refractory prostate cancer, suggesting that better AR inhibitors than the current drugs can slow the progression of prostate cancer. It was demonstrated that AR and its ligand binding are necessary for growth of hormone refractory prostate cancer indicating that AR is still a target for this disease t was also demonstrated that overexpression of AR converts anti-androgens from antagonists to agonists in hormone refractory prostate cancer (an AR antagonist inhibits AR activity and an AR agonist stimulates AR activity). Data from this work explains why castration and anti-androgens fail to prevent prostate cancer progression and reveals unrecognized properties of hormone refractory prostate cancer. Antigonadotropins like estrogens and progestogens were both fi rs introduced in the 1930s. AR antagonists were first discovered in the early 1960s. The steroidal antiandrogencyproterone acetate was discovered in 6 1 and introduced in 1973 and is often described as the first antiandrogen to have been marketed. However spironolactone was introduced in 1959, and although its antiandrogen effects were not recognized or taken advantage of until later and were originally an unintended off- target action of the drug, it may be more appropriate to regard it as the fi rs antiandrogen to have been introduced. In addition to spironolactone, chlormadinone acetate and raegestrol acetate are steroidal antiandrogens that are weaker than cyproterone acetate but were also introduced earlier, in the 1960s. Other early steroidal antiandrogens that were developed around this time but were never marketed include benorterone (SKF-7690; 17a-methyl-B-nortestosterone), BOMT (Ro 7- 2340), cyproterone (SH-80881), and trimethyltrienolone (R-2956). The nonsteroidal antiandrogenflutamide was first reported in 1967. It was introduced in 1983 and was the first nonsteroidaiantiandrogen to be marketed. Another early nonsteroidaiantiandrogen, D MP (Ro 7-8117), which is structurally related to thalidomide and is a relatively weak antiandrogen, was first described in 1973 and was never marketed. Rutamide was followed by nilutamide in 1989 and bicalutamide in 1995. n addition to these three drugs, which have been regarded as first-generation nonsteroidalantiandrogens, the second-generation nonsteroidaiantiandrogen enzalutamide was introduced in 2012. It differs from the earlier nonsteroidalantiandrogens namely in that it is much more efficacious in comparison. The androgen synthesis inhibitors aminogluteihimide and ketoconazole were first marketed in 1960 and 1977, respectively, and the newer drug abiraterone acetate was introduced in 2011.GnRH analogues were first introduced in the 1980s. The 5a- reductase inhibitors finasteride and dutasteride were introduced in 1992 and 2002, respectively. A nonsteroidaiantiandrogen (NSAA) is an antiandrogen with a nonsteroidal chemical structure. They are typically selective and full or silent antagonists of the androgen receptor (AR) and act by blocking the effects of androgens like testosterone and dihydrotestosterone (D T). SAAs are used in the treatment of androgen -dependent conditions in men and women. They are the converse of steroidal antiandrogens (SAAs), which are antiandrogens that are steroids and are structurally related to testosterone. Bicalutamide (brand name: Casodex®) is the most commonly used anti-androgen. While it has an inhibitory effect on AR in hormone sensitive prostate cancer, it fails to suppress AR when cancer becomes hormone refractory.